Cell Biology Program
The Lydia Finley Lab
The Finley Lab investigates how cellular metabolic pathways regulate cell fate decisions in stem cells and cancer cells. We combine genetic and metabolomic approaches to investigate cell-type specific growth requirements and elucidate how flux through central metabolic pathways regulates key cellular activities, including self-renewal and differentiation. In particular, we are interested in understanding how changes in metabolite availability shape the chromatin landscape to influence gene expression programs that control cell survival, growth and differentiation. Our work aims to answer fundamental questions about how cells regulate the commitment to differentiation and how failure to execute terminal differentiation can underlie diseases such as cancer.
α-Ketoglutarate links p53 to cell fate during tumour suppression. Morris JP 4th*, Yashinskie JJ*, Koche R, Chandwani R, Tian S, Chen CC, Baslan T, Marinkovic ZS, Sánchez-Rivera FJ, Leach SD, Carmona-Fontaine C, Thompson CB, Finley LWS#, Lowe SW#. Nature. 2019 Sep;573(7775):595-599. doi: 10.1038/s41586-019-1577-5. Epub 2019 Sep 18. PMID: 31534224. (*co-first, #co-corresponding)
Glutamine independence is a selectable feature of pluripotent stem cells. Vardhana SA, Arnold PK, Rosen BP, Chen Y, Carey BW, Huangfu D, Fontaine CC, Thompson CB, Finley LWS. Nat Metab. 2019 Jul;1(7):676-687. doi: 10.1038/s42255-019-0082-3. Epub 2019 Jul 8. PMID: 31511848
Lydia Finley, PhD
- Lydia Finley studies the mechanisms that link metabolic pathways to cell fate decisions.
- PhD, Harvard University
- Searle Scholars Program
- Damon Runyon-Dale F. Frey Award for Breakthrough Scientists
- Jack Sorrell Fellow of the Damon Runyon Cancer Research Foundation
Lab News & Events
To learn more about available postdoctoral opportunities, please visit our Career Center
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Lydia Finley discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.